TAG
#biotech
Stories connected through a shared idea, actor, technology or theme.
OpenAI acquires Orchestra Bio to expand Rosalind’s drug-development capabilitiesOrchestra’s agents monitor studies, campaigns and dependencies across biopharma programmes. OpenAI said the acquisition will support agents that connect scientific findings with studies, decisions and next steps needed to advance medicines.→AstraZeneca signs up to $1.5 billion AI drug-discovery deal with insitroAstraZeneca will pay $40 million upfront, with insitro eligible for up to approximately $1.46 billion in development and commercial milestones. Insitro will use its Virtual Human platform to identify causal disease biology for MASH and cardiomyopathies.→AbbVie and Iambic partner on AI-driven small-molecule discoveryThe partnership will use Iambic’s Enchant v3 model and NeuralPLexer technology to evaluate many molecular properties and design hypotheses in parallel. Iambic will receive an upfront payment and may receive milestone payments and royalties, but the release does not disclose the financial terms or clinical outcomes of the collaboration.→Nona Biosciences reports a human heavy-chain antibody language modelNona Biosciences announced HCAbLM on 16 September and said the accompanying study was posted to bioRxiv. The 366-million-parameter model was trained on sequences from 73 independently immunised transgenic mice; the company says it outperformed Meta's ESM-6B, IgLM and AbLang on SEC-purity and HIC-behaviour tests and transferred to thermal-stability prediction.→Insilico study reports biological-age signal for AI-designed drug candidateThe study examined 42 patients with idiopathic pulmonary fibrosis and reported lower predicted biological age across six independent proteomic clocks after treatment. The findings are biomarker results and do not establish that the drug reverses ageing or improves longevity.→